NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

March 16, 2005 11:05 ET

European Studies Show That Nymox's NicAlert Product Improves Smoking Cessation Success Rates


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: NYMOX PHARMACEUTICAL

NASDAQ SYMBOL: NYMX

MARCH 16, 2005 - 11:05 ET

European Studies Show That Nymox's NicAlert Product
Improves Smoking Cessation Success Rates

MAYWOOD, N.J.--(CCNMatthews - Mar 16, 2005) -

Nymox Pharmaceutical Corporation's (NASDAQ: NYMX) NicAlert™ has been
shown to increase nicotine replacement therapy (NRT) success according
to a team of Swiss researchers led by Dr. Karl Klingler of the
Hirslanden Lung Center, Zurich, Switzerland. The researchers have found
that the success rate was significantly improved when NicAlert™ was
used in conjunction with NRT to measure nicotine consumption.

Dr. Klinger said, "the benefit of using NRT for smoking cessation is
clearly affected by proper dosing. Using NicAlert™ to accurately
measure nicotine consumption has been shown to increase the efficacy of
NRT therapy by 26%."

NicAlert™ is a powerful one-step patented urine test for detecting
smoking and tobacco product exposure that combines the advantages of
semi-quantitative measurement together with an easy-to-use, cost
effective, rapid format. NicAlert™ does not require any instruments
or special training for its use.

Nymox's NicAlert™ has received clearance from the U.S. FDA.

Brian Doyle, Nymox's Global Sales Manager said, "NicAlert™ offers a
cost-effective way of determining smoking status right on-site. It does
not require any special instruments or skills and gives accurate results
within minutes. We believe that it can be a valuable tool in the
campaign to get smokers to quit before it is too late."

Physicians should routinely assess, review and document the smoking
status of every patient, according to A Clinical Practice Guideline for
Treating Tobacco Use and Dependence (JAMA 2000; 283:3244-54) issued by
the U.S. Public Health Service and formal policy positions adopted by
the American Medical Association, the American Heart Association, the
American Academy of Family Physicians, the American Diabetes Association
and other medical associations. Studies have shown that a significant
percentage of patients at risk do not always truthfully report their
smoking status.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. Such factors are detailed from time to time in
Nymox's filings with the United States Securities and Exchange
Commission and other regulatory authorities.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com